Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The effects of gliclazide in diabetes : a comparison with tolbutamide

  • 28 Accesses

  • 5 Citations


A STUDY was carried out to examine the effect of Gliclazide on Type I insulin dependent, and Type 2 insulin independent diabetic patients. Both Gliclazide and Tolbutamide increased HDL cholesterol in Type 2 diabetic patients (1.24±0.1→;1.72±0.15 mmol/l, p< 0.05. 1.42±0.1→1.68 ± 0.1 mmol/l, p< 0.05). This improvement appeared to be independent of any improvement in diabetic control in patients on Gliclazide. Gliclazide had no effect on Type 1 diabetic patients on insulin. These results may suggest a protective mechanism for Type 2 maturity onset diabetic patients treated with a sulphonylurea drug.

This is a preview of subscription content, log in to check access.


  1. Burnstein, M., Scholnick, W. R. 1973. Advances in Lipid Research. Ed. by Paoletti and Kritcheysky. Academic Press, New York, 67–108.

  2. Calvert, G. 1978. Effects of therapy on plasma high density lipoprotein cholesterol concentration in diabetes mellitus. Lancet ii, 66–68.

  3. Charbonnell, B. 1977. A new approach to the treatment of diabetic disease. Volume Therapeutique des Entretiens de Bichat.i 187–192.

  4. Editorial. 1980. Lancet i, 464–465.

  5. Kazawosian, M., Riveline, B., Dagrue, G. 1976. Diabetic microangiopathy : study in a department of nephrology during long-term treatment with Gliclazide. Gazette Medicale de France. 83, No. 9.

  6. Keen, H. 1970. Minimal diabetes and arterial disease: prevalence and the effect of treatment. Early Diabetes. Ed. by R. Camerini-Davalos, H. Cole. Academic Press, New York.

  7. Klaff, L. J., Vinik, A. I., Mahon, E., Kernoff, L., Jacobs, P. 1979. 7ffects of the sulphonylurea drugs Gliclazide and Glibenclamide on blood glucose control and platelet function. South African Med. J. 56, 247–249.

  8. Mattork, M., Fuller, J., Maude, P. S., Keen, H. 1979. Lipoproteins and plasma cholesterol esterification in normal and diabetic subjects. Atherosclerosis 34, 437–449.

  9. Paasikivi, J. 1970. Long term Tolbutamide treatment after myocardial infarction. Acta Medica Scandanavica. Suppl. vol. 507–517.

  10. Ponari, O., Civardi, E., Magha, S., Pini, M., Portioli, D., Dettori, A. G. 1979. Anti-platelet effect of long term treatment with Gliclazide in diabetic patients. Thrombosis Research 16, 191–203.

  11. Pyke D. A. 1979. The genetic connections. Diabetologie 17, 333–343.

  12. Welsh, S. G., Boucher, J. 1978. A rapid micros scale method for the measurement of Haemoglobin A1. Diabetologia 14, 209–211.

  13. Witzum, J., Schonfeld, S. 1979. High density lipoproteins. Diabetes 28, 326–336.

Download references

Author information

Correspondence to M. J. Berber or G. H. Tomkin.

Additional information

We wish to thank Miss R. Bloomgart for carrying out the HbA1 estimation.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Berber, M.J., Tomkin, G.H. The effects of gliclazide in diabetes : a comparison with tolbutamide. Ir J Med Sci 151, 46–49 (1982). https://doi.org/10.1007/BF02940142

Download citation


  • Blood Sugar
  • High Density Lipoprotein Cholesterol
  • Diabetic Control
  • Tolbutamide
  • Gliclazide